Lilac Solutions vs Armilla AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Oakland DLE lithium extraction technology ($318M total, $145M T. Rowe Price Series C); 5th gen 20x production rates with 1-acre = 10,000-acre evaporation pond efficiency and Great Salt Lake/Argentina deployments competing with SLB for lithium supply.
About
Lilac Solutions is an Oakland, California-based direct lithium extraction (DLE) technology company — backed with over $318 million in total funding including a $145 million Series C led by T. Rowe Price and Presidio Ventures — commercializing a proprietary ion exchange process that extracts lithium from brine resources with 70-98% efficiency using ceramic beads coated with nano-materials, achieving the same lithium output from a 1-acre system that conventional evaporation pond methods require 10,000 acres to produce. Founded in 2016 from CEO Dave Snydacker's PhD research at Northwestern University, Lilac was acquired new CEO Raef Sully (former CEO of Nutrien's $10 billion business unit) in 2024 to lead commercial scaling. In 2025, Lilac unveiled its fifth-generation DLE technology achieving 20x higher lithium production rates and 10,000 operational cycles before replacement — orders of magnitude better than competing technologies. Active projects include the Kachi project in Argentina (with Lake Resources), the Great Salt Lake project in Utah (targeting 3,000 tonnes per year by 2026), and the Neptune project in Germany. Lilac's manufacturing facility in Fernley, Nevada produces the ion exchange beads for commercial deployment. Investors include Breakthrough Energy Ventures.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
About
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
AI Visibility Head-to-Head
Also Compare
Lilac Solutions vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.